Snapshot from Jul 30, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Regulatory / Curaleaf registers cannabis in Spain
Regulatory regulatory approval

Curaleaf registers cannabis in Spain

Analysis based on 8 articles · First reported Jul 13, 2026 · Last updated Jul 13, 2026

Sentiment
30
Attention
2
Articles
8
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

This regulatory milestone positions Curaleaf as a first mover in Spain's emerging medicinal cannabis market, potentially boosting its European revenue. The approval may also signal a broader opening for cannabis companies in Spain, increasing competition and market growth.

cannabis pharmaceuticals
Event Summary

Curaleaf Holdings, Inc. announced that the Spain — Spanish Agency of Medicines and Medical Devices (AEMPS) has approved the registration of two standardized cannabis preparations (THC-dominant and CBD-dominant) under Spain's new regulatory framework, Royal Decree 903/2025. Curaleaf is the first company to register such preparations in Spain, marking a milestone for medicinal cannabis access. The registrations build on Curaleaf's existing EU-GMP certified facility in Alicante and its 2020 license from AEMPS. The preparations are expected to become available to patients through hospital pharmacies as the framework is implemented.

Key Actions
100 Spain — Spanish Agency of Medicines and Medical Devices approved registration Curaleaf
30 Curaleaf secured first license
Entities Involved
stock
Curaleaf
Curaleaf secured the first registration of standardized cannabis preparations in Spain under the new Royal Decree 903/2025, strengthening its leadership in the European medicinal cannabis market and potentially increasing its market share and revenue.
Importance 100.0 Sentiment 60.0
govactor
Spain — Spanish Agency of Medicines and Medical Devices
AEMPS approved the registration of Curaleaf's cannabis preparations, implementing the new regulatory framework and enabling patient access to standardized cannabis medicines through hospital pharmacies.
Importance 80.0 Sentiment 20.0
cnt
Spain
Spain's new regulatory framework for medicinal cannabis, Royal Decree 903/2025, is being implemented with Curaleaf's registration as a first step, potentially expanding patient access and creating a new market for cannabis products.
Importance 70.0 Sentiment 30.0
per
Boris Jordan
As CEO and Chairman of Curaleaf, Boris Jordan announced the registration milestone, highlighting the company's long-term investment in Spain and its commitment to providing standardized cannabis medicines.
Importance 30.0 Sentiment 40.0
priv
Medalchemy SL
Medalchemy SL, Curaleaf's EU-GMP certified laboratory in Alicante, secured the first license from AEMPS in 2020 to process medicinal cannabis derivatives, laying the foundation for the current registration.
Importance 20.0 Sentiment 30.0
exch
Toronto Stock Exchange
Curaleaf is listed on the Toronto Stock Exchange under the symbol CURA; the registration news may positively affect its stock price and trading activity.
Importance 10.0 Sentiment 10.0
exch
OTC Markets Group
Curaleaf trades on the OTCQX market under the symbol CURLF; the registration news may influence its over-the-counter trading performance.
Importance 10.0 Sentiment 10.0
Relationships
Curaleaf related ↔ Boris Jordan
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.